(Reuters) - Neurocrine Biosciences Inc said its movement disorder drug showed a reduction in symptoms compared to a placebo in a mid-stage study, sending its shares up 56 percent after the bell. The trial tested the drug, NBI-98854, in 102 moderate to severe tardive dyskinesia patients over a six-week treatment period. Tardive dyskinesia is a movement disorder that affects a person's ability to perform voluntary muscular movements. It is characterized by symptoms including lip smacking, facial movements or blinking, or involuntary movements of the limbs. via Health News Headlines - Yahoo News Read More Here..
Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2014/01/neurocrine-movement-disorder-drug-meets_6.html
No comments:
Post a Comment